| Piloting Mindfulness Meditation Program for Underserved Racial Minority Adults With Pulmonary Hypertension (NCT05387889) | State University of New York at Buffalo | 2022-06-17 |
| A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option (NCT05179876) | Actelion | 2022-05-04 |
| A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) (NCT04945460) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2021-12-29 |
| A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007) (NCT04732221) | Merck Sharp & Dohme LLC | 2021-05-19 |
| A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study (NCT04565990) | Actelion | 2021-05-03 |
| Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension Receiving Sildenafil (NCT04697862) | University of Zurich | 2021-02-01 |
| Blood Markers Predict Effect of Normobaric Hypoxia at Rest and During Exercise in Patients With Pulmonary Hypertension (NCT04715113) | University of Zurich | 2021-02-01 |
| Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension With/Without Sildenafil (NCT04704440) | University of Zurich | 2021-02-01 |
| Feasibility and Safety of Total Percutaneous Closure of Femoral Arterial Access Sites in the Veno-arterial ECMO Patients (NCT04689451) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-02-01 |
| Hemodynamic Effects of Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension (NCT04697875) | University of Zurich | 2021-02-01 |
| Treatment of Pulmonary Hypertension in High-risk Cardiac Surgery Patients Using Inhalational and Intravenous Agents (NCT04718350) | Aretaieion University Hospital | 2021-01-27 |
| A Study for the Identification of Biomarker Signatures for Diagnosis of Pulmonary Hypertension (PH) in Participants at Low or Intermediate Probability of PH Undergoing Cardiac Magnetic Resonance Imaging (NCT04480723) | Actelion | 2020-12-11 |
| Exercise Hemodynamic, Right Ventricular Coupling and Echocardiography in Pulmonary Hypertension (NCT04663217) | University of Giessen | 2020-11-01 |
| Levosimendan Administration in Pulmonary Hypertension (NCT04599816) | Aretaieion University Hospital | 2020-10-17 |
| THERAPY-HYBRID-BPA Trial (NCT04600492) | National Hospital Organization Okayama Medical Center | 2020-10-16 |
| Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness (NCT04498299) | Miguel Ayala León | 2020-09-01 |
| The Prevalence of Pulmonary Hypertension in Patients With COVID-19. (NCT04459364) | Attgeno AB | 2020-06-01 |
| A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH) (NCT04193046) | Janssen Research & Development, LLC | 2019-12-16 |
| Effects of Inspiratory Muscle Training in Patients With Pulmonary Hypertension (NCT04152187) | Dokuz Eylul University | 2019-11-11 |
| Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants (NCT04095286) | GlaxoSmithKline | 2019-09-30 |
| A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension (NCT03683186) | United Therapeutics | 2019-09-23 |
| Acute Decompensation of Pulmonary Hypertension (NCT03926572) | Assistance Publique - Hôpitaux de Paris | 2019-09-19 |
| Pedometers and Walking Tests for Pulmonary Hypertension Patients (NCT03810482) | University Hospital, Montpellier | 2019-03-21 |
| A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (NCT03626688) | United Therapeutics | 2019-01-24 |
| This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (NCT03754660) | Bayer | 2019-01-21 |
| Inflammatory Biomarkers of Pediatric Pulmonary Hypertension (NCT03581695) | The Hospital for Sick Children | 2018-06-20 |
| Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension (NCT03388476) | University of Giessen | 2018-05-02 |
| ORal IrON Supplementation With Ferric Maltol in Patients With Pulmonary Hypertension (ORION-PH-1) (NCT03371173) | Hannover Medical School | 2018-03-27 |
| A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH) (NCT03177603) | GlaxoSmithKline | 2018-02-21 |
| Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension (NCT03293407) | Bayer | 2018-02-01 |
| Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects (NCT03304548) | GlaxoSmithKline | 2017-11-22 |
| Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension (NCT03001414) | Northern Therapeutics | 2017-09-28 |
| Aerobic Interval Training in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Hypoxemia (NCT03092622) | Norwegian University of Science and Technology | 2017-04-01 |
| Acute Hemodynamic Effect of Acetazolamide in Pulmonary Hypertension (NCT02755259) | University of Zurich | 2017-01-01 |
| The Evaluation and Treatment of Elevated Left-Sided Filling Pressures by Balloon Inflation Within the IVC (NCT02984631) | Cardioflow Technologies, LLC | 2016-12-01 |
| Chronic Clinical Effect of Acetazolamide (NCT02755298) | University of Zurich | 2016-10-01 |
| Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea. (NCT02963597) | Albert Einstein Healthcare Network | 2016-10-01 |
| Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20) (NCT02826252) | Bayer | 2016-09-15 |
| Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH) (NCT02825160) | Bayer | 2016-08-01 |
| A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension. (NCT02759419) | Bayer | 2016-06-16 |
| AZ, MZ, and the Pulmonary System Response to Hypoxia (NCT02760121) | University of British Columbia | 2016-05-01 |
| Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial) (NCT02435303) | Asan Medical Center | 2016-05-01 |
| A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects (NCT02688387) | GlaxoSmithKline | 2016-03-18 |
| A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries (NCT02637050) | Bayer | 2016-03-03 |
| Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (NCT02744339) | Medical University of Vienna | 2016-03-01 |
| Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion (NCT02217683) | Massachusetts General Hospital | 2016-03-01 |
| The Exercise Capacity and Quality of Life in the Patients With IPAH and Secondary PH (NCT02647060) | National Taiwan University Hospital | 2016-01-13 |
| Effects of Different Types of Physical Training in Patients With Pulmonary Arterial Hypertension. (NCT03476629) | University of Nove de Julho | 2016-01-10 |
| Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients (NCT02551653) | GlaxoSmithKline | 2015-11-17 |
| Estimation of Pulmonary Capillary Blood Volume in Pre- and Postcapillary Pulmonary Hypertension (NCT02789449) | Medical University of Graz | 2015-11-01 |
| Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (NCT02562235) | Bayer | 2015-10-29 |
| Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension) (NCT02576002) | Bayer | 2015-10-01 |
| Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension (NCT03043976) | Imperial College Healthcare NHS Trust | 2015-10-01 |
| A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice (NCT02545465) | Bayer | 2015-09-15 |
| Effect of Exercise Training in Patients With Pulmonary Hypertension (NCT02558582) | University of Zurich | 2015-09-01 |
| Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension (NCT02610660) | Association for Pediatric Pulmonary Hypertension | 2015-08-01 |
| Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension (NCT02536534) | Bayer | 2015-06-30 |
| Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH) (NCT02428985) | Bayer | 2015-06-29 |
| The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals (NCT02560116) | Northwell Health | 2015-06-01 |
| A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation (NCT02305550) | Massachusetts General Hospital | 2015-04-01 |
| Catheter Denervation of Pulmonary Arteries in Treatment of IPAH & SPAH (NCT02403908) | Clinical Hospital Centre Zagreb | 2015-02-01 |
| Safety Procedure Pulmonary Artery Denervation in Addition to Pulmonary Vein Isolation Combined With Ganglionated Plexi Ablation in Patients With Persistent Atrial Fibrillation and Pulmonary Hypertension (NCT02298244) | Krasnoyarsk Regional Hospital | 2015-01-01 |
| The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD (NCT02267200) | Shanghai Jiao Tong University School of Medicine | 2014-10-01 |
| Measurement of Endothelial Function and Cardiac Output: New Methods (NCT02299960) | Charite University, Berlin, Germany | 2014-08-01 |
| Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) (NCT02117791) | Bayer | 2014-07-16 |
| EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension (NCT02092818) | Bayer | 2014-05-31 |
| Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (NCT02007629) | Bayer | 2014-02-18 |
| A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH) (NCT01824290) | Eli Lilly and Company | 2014-02-05 |
| Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude (NCT02024386) | Richard Moon | 2014-01-01 |
| Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension (NCT01971450) | Bayer | 2013-11-21 |
| Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery (NCT01959828) | Mallinckrodt | 2013-09-01 |
| Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension (NCT01642407) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2012-08-24 |
| Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension (NCT01523548) | University of Illinois at Chicago | 2012-07-01 |
| Effects Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome (NCT02661802) | Federal University of São Paulo | 2012-01-01 |
| Dietary Nitrate for Heart Failure (NCT01682356) | Washington University School of Medicine | 2012-01-01 |
| Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) (NCT01462565) | GlaxoSmithKline | 2011-11-01 |
| Diagnosis of Cardio-Pulmonary Pathology Using Transthoracic Parametric Doppler (TPD) (NCT01361139) | Echosense Ltd. | 2011-08-01 |
| Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: Prevalence and Quality of Life (NCT01423071) | Wissenschaftliches Institut Bethanien e.V | 2011-08-01 |
| Predictors of Pulmonary Hypertension Risk in Premature Infants With Bronchopulmonary Dysplasia (NCT01516398) | Stanford University | 2011-07-01 |
| Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529 (NCT01342952) | GlaxoSmithKline | 2011-06-21 |
| Efficacy and Safety of Ambrisentan in Children 8-18yrs (NCT01332331) | GlaxoSmithKline | 2011-01-04 |
| Observation Study of the Medication Switch at Patients Treated With Sitaxentan to a Regime Without Sitaxentan (NCT01281371) | Heidelberg University | 2011-01-01 |
| Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension) (NCT01406327) | GlaxoSmithKline | 2010-12-14 |
| Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics (NCT01065051) | Bayer | 2010-11-01 |
| Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients (NCT01210443) | Pfizer | 2010-11-01 |
| A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (NCT01178073) | GlaxoSmithKline | 2010-10-01 |
| Endothelial Function in Patients With Pulmonary Arterial Hypertension (NCT01317134) | Universitätsklinikum Hamburg-Eppendorf | 2010-10-01 |
| Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients (NCT01202045) | Paul Farand | 2010-09-01 |
| A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients (NCT01204853) | Pfizer | 2010-08-01 |
| A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil). (NCT01305252) | Stanford University | 2010-07-01 |
| A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction (NCT01172756) | Bayer | 2010-07-01 |
| A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (NCT01065454) | Bayer | 2010-04-14 |
| Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH) (NCT01038284) | University Hospital, Grenoble | 2010-03-01 |
| First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension (NCT01247116) | University of Calgary | 2009-12-01 |
| Effects of Propofol and Isoflurane on Pulmonary Vascular Resistance (NCT01212523) | University Hospitals Bristol and Weston NHS Foundation Trust | 2009-11-01 |
| Effect of Food on the Pharmacokinetics of Oral Treprostinil (NCT00963001) | United Therapeutics | 2009-09-01 |
| Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil (NCT00963027) | United Therapeutics | 2009-09-01 |
| Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (NCT01121458) | North Texas Veterans Healthcare System | 2009-09-01 |
| A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension (NCT00853112) | Pfizer | 2009-04-01 |
| A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (NCT00864201) | Hamilton Health Sciences Corporation | 2009-04-01 |